CTOs on the Move

Savara Pharmaceuticals

www.savarapharma.com

 
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.savarapharma.com
  • 6836 Bee Cave Road Building 3, Suite 200
    Austin, TX USA 78746
  • Phone: 512.961.1891

Executives

Name Title Contact Details

Funding

Savara Pharmaceuticals raised $18.54M on 12/17/2015
Savara Pharmaceuticals raised $47M on 10/26/2017
Savara Pharmaceuticals raised $26.8M on 01/15/2020
Savara Pharmaceuticals raised $130M on 03/11/2021

Similar Companies

Pharm-RX Chemical Corp

Pharm-RX Chemical Corp is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.

PharmaExpressRx

PharmaExpressRx is a Addison, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

L.B. Bohle

L.B. Bohle, LLC is a Warminster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.